Citations

Showing 10 of 108162 citations.

Short and long‐term outcomes of three‐dimensional printed surgical guides and virtual surgical planning versus conventional methods for fibula free flap reconstruction of the mandible: Decreased nonunion a
May, Matthew M. , Howe, Benjamin M., O’Byrne, Thomas J., Alexander, Amy E. , Morris, Jonathon M., Moore, Eric J. , Kasperbauer, Jan L. , Janus, Jeffrey R. , Abel, Kathryn M. Van , Dickens, Hunter J., Van Abel, Kathryn M , Howe, Benjamin M. , Price, Daniel L.

Mayo Clinic

Head & Neck | March 31, 2021 | Volume: 43 | Issue: 8 | Pages: 2342-2352

10.1002/hed.26688 | PMID 33786910 Get It

Abstract Background To determine whether virtual surgical planning and three‐dimensional printed cutting guides (3D/VSP) improved radiographic bone union compared to conventional methods (CM) in fibula free flap (FFF) reconstruction of the mandibles. Methods Retrospective study from the years 2000–2018 at a tertiary hospital. Osseous union was evaluated by a radiologist blinded to each patient's treatment. Results Two hundred sixty patients who underwent FFF tissue transfer, 28 with VSP and 3D cutting guides. Bony union was not achieved in 46 (20%) patients who underwent CM compared to 1 (4%) of patients with VSP and guides ( p = 0.036). FFF complication was significantly higher in CM with 87 patients (38%) compared to three patients (11%) in 3D/VSP ( p = 0.005). Median time to bony union for patients who underwent CM was 1.4 years compared to 0.8 years in 3D/VSP. Conclusions 3D/VSP reduced the rate of radiographic nonunion and flap‐related complications in FFF reconstruction for mandibular defects.
Artificial Intelligence (AI)-Empowered Echocardiography Interpretation: A State-of-the-Art Review
Akkus, Zeynettin , Aly, Yousof H., Attia, Itzhak Z., Arruda‐Olson, Adelaide M. , Pellikka, Patricia A. , Kane, Garvan C. , Friedman, Paul A. , Oh, Jae K. , Pellikka, Patricia A , Akkus, Zeynettin , Attia, Itzhak Z., López-Jiménez, Francisco , Pislaru, Sorin V.

Mayo Clinic

Journal of Clinical Medicine | March 31, 2021 | Volume: 10 | Issue: 7 | Pages: 1391

10.3390/jcm10071391 | PMID 33808513 Get It

Echocardiography (Echo), a widely available, noninvasive, and portable bedside imaging tool, is the most frequently used imaging modality in assessing cardiac anatomy and function in clinical practice. On the other hand, its operator dependability introduces variability in image acquisition, measurements, and interpretation. To reduce these variabilities, there is an increasing demand for an operator- and interpreter-independent Echo system empowered with artificial intelligence (AI), which has been incorporated into diverse areas of clinical medicine. Recent advances in AI applications in computer vision have enabled us to identify conceptual and complex imaging features with the self-learning ability of AI models and efficient parallel computing power. This has resulted in vast opportunities such as providing AI models that are robust to variations with generalizability for instantaneous image quality control, aiding in the acquisition of optimal images and diagnosis of complex diseases, and improving the clinical workflow of cardiac ultrasound. In this review, we provide a state-of-the art overview of AI-empowered Echo applications in cardiology and future trends for AI-powered Echo technology that standardize measurements, aid physicians in diagnosing cardiac diseases, optimize Echo workflow in clinics, and ultimately, reduce healthcare costs.
Decoding Saccade Intention From Primate Prefrontal Cortical Local Field Potentials Using Spectral, Spatial, and Temporal Dimensionality Reduction
Johnston, Renée , Doucet, Guillaume , Miller, Kai J. , Martínez-Trujillo, Julio , Boulay, Chadwick , Sachs, Adam J.

Mayo Clinic

International Journal of Neural Systems | March 30, 2021 | Volume: 31 | Issue: 06 | Pages: 2150023

10.1142/s0129065721500234 | PMID 33931006 Get It

Most invasive Brain Computer Interfaces (iBCIs) use spike and Local Field Potentials (LFPs) from the motor or parietal cortices to decode movement intentions. It has been debated whether harvesting signals from other brain areas that encode global cognitive variables, such as the allocation of attention and eye movement goals in a variety of spatial reference frames, may improve the outcome of iBCIs. Here, we explore the ability of LFP signals, sampled from the lateral prefrontal cortex (LPFC) of macaque monkeys, to encode eye-movement intention during the pre-movement fixation period of a delayed saccade task. We use spectral dimensionality reduction to examine the spatiotemporal properties of the extracted non-rhythmic broadband activity and explore its usefulness in decoding saccade goals. The dynamics of the broadband signal in low spatial dimensions across the pre-movement fixation period uncovered saccade target separation; its discriminative potential was confirmed using support vector machine classifications. These findings reveal that broadband LFP from the LPFC can be used to decode intended saccade target location during pre-movement periods. We further provide a general workflow that can be implemented in iBCIs and it is relatively robust to the loss of spikes in individual electrodes.
Pharmacological Profile and Ocular Hypotensive Effects of Cromakalim Prodrug 1, a Novel ATP-Sensitive Potassium Channel Opener, in Normotensive Dogs and Nonhuman Primates
Chowdhury, Uttio Roy, Kudgus, Rachel A. , Holman, Bradley H., Rinkoski, Tommy A. , Hann, Cheryl R., Bahler, Cindy K., McCloud, Eric, Appt, Susan E. , Fautsch, Michael P. , Roy Chowdhury, Uttio, Reid, Joel M. , McCloud, Eric, Dosa, Peter I.

Mayo Clinic

Journal of Ocular Pharmacology and Therapeutics | March 30, 2021 | Volume: 37 | Issue: 5 | Pages: 251-260

10.1089/jop.2020.0137 | PMID 33784195 Get It

Purpose: To evaluate pharmacokinetic parameters and ocular hypotensive effects of cromakalim prodrug 1 (CKLP1) in normotensive large animal models. Methods: Optimal CKLP1 concentration was determined by dose response and utilized in short- (5–8 days) and long-term (60 days) evaluation in hound dogs ( n = 5) and African Green Monkeys ( n = 5). Blood pressure was recorded 3–5 times per week with a tail cuff. Concentrations of CKLP1 and the parent compound levcromakalim were assessed in hound dog plasma and select tissues by LC-MS/MS after bilateral ocular treatment with CKLP1 for 8 days. Pharmacokinetic parameters were calculated from days 1, 4, and 8 data. After necropsy, histology was assessed in 43 tissue samples from each animal. Results: In hound dogs and African Green monkeys, 10 mM CKLP1 (optimal concentration) significantly lowered intraocular pressure (IOP) by 18.9% ± 1.1% and 16.7% ± 6.7%, respectively, compared with control eyes ( P < 0.05). During treatment, no significant change in systolic or diastolic blood pressure was observed in either species ( P > 0.1). Average values for half-life of CKLP1 was 295.3 ± 140.4 min, C max, 10.5 ± 1.6 ng/mL, and area under the concentration vs. time curve (AUC last ) 5261.4 ± 918.9 ng·min/mL. For levcromakalim, average values of half-life were 96.2 ± 27 min, C max 1.2 ± 0.2 ng/mL, and AUC last 281.2 ± 110.8 ng·min/mL. No significant pathology was identified. Conclusions: CKLP1 lowered IOP in hound dogs and African green monkeys with no effect on systemic blood pressure. Ocular topical treatment of CKLP1 showed excellent tolerability even after extended treatment periods.
The Difference in Facial Movement Between the Medial and the Lateral Midface: A 3-Dimensional Skin Surface Vector Analysis
Freytag, David L., Alfertshofer, Michael , Frank, Konstantin , Swift, Arthur, Heisinger, Stephan , Ehrl, Denis , Velthuis, Peter J. , Alfertshofer, Michael , Frank, Konstantin , Melnikov, D. V. , Moellhoff, Nicholas , Gotkin, Robert H. , Cotofana, Sebastian

Mayo Clinic

Aesthetic Surgery Journal | March 30, 2021 | Volume: 42 | Issue: 1 | Pages: 1-9

10.1093/asj/sjab152 | PMID 33784397 Get It

Abstract Background Our understanding of the functional anatomy of the face is constantly improving. To date, it is unclear whether the anatomic location of the line of ligaments has any functional importance during normal facial movements such as smiling. Objectives The authors sought to identify differences in facial movements between the medial and lateral midface by means of skin vector displacement analyses derived from 3-dimensional (3D) imaging and to further ascertain whether the line of ligaments has both a structural and functional significance in these movements. Methods The study sample consisted of 21 healthy volunteers (9 females and 12 males) of Caucasian ethnic background with a mean age of 30.6 (8.3) years and mean BMI of 22.57 (2.5) kg/m2. 3D images of the volunteers’ faces in repose and during smiling (Duchenne type) were taken. 3D imaging-based skin vector displacement analyses were conducted. Results The mean horizontal skin displacement was 0.08 (2.0) mm in the medial midface (lateral movement) and was −0.08 (1.96) mm in the lateral midface (medial movement) (P = 0.711). The mean vertical skin displacement (cranial movement of skin toward the forehead/temple) was 6.68 (2.4) mm in the medial midface, whereas it was 5.20 (2.07) mm in the lateral midface (P = 0.003). Conclusions The results of this study provide objective evidence for an antagonistic skin movement between the medial and lateral midface. The functional boundary identified by 3D imaging corresponds to the anatomic location of the line of ligaments. Level of Evidence: 4
Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE ɛ3/ɛ4 Carriers
Edlund, Anna , Lee, Wendy , Protas, Hillary , Su, Yi , Reiman, Eric M. , Caselli, Richard J. , Nielsen, Henrietta M. , Reiman, Eric, Edlund, Anna K., Chen, Kewei

Mayo Clinic

Journal of Alzheimer's Disease | March 30, 2021 | Volume: 81 | Issue: 1 | Pages: 339-354

10.3233/jad-210065 | PMID 33814450 Get It

Background: Altered cerebral glucose metabolism, especially prominent in APOE ɛ4 carriers, occurs years prior to symptoms in Alzheimer’s disease (AD). We recently found an association between a higher ratio of plasma apolipoprotein E4 (apoE4) over apoE3, and cerebral glucose hypometabolism in cognitively healthy APOE ɛ3/ɛ4 subjects. Plasma apoE does not cross the blood-brain barrier, hence we speculate that apoE is linked to peripheral glucose metabolism which is known to affect glucose metabolism in the brain. Objective: Explore potential associations between levels of plasma insulin and glucose with previously acquired plasma apoE, cerebral metabolic rate of glucose (CMRgl), gray matter volume, and neuropsychological test scores. Methods: Plasma insulin and glucose levels were determined by ELISA and a glucose oxidase assay whereas apoE levels were earlier quantified by mass-spectrometry in 128 cognitively healthy APOE ɛ3/ɛ4 subjects. Twenty-five study subjects had previously undergone FDG-PET and structural MRI. Results: Lower plasma apoE3 associated with higher plasma glucose but not insulin in male subjects and subjects with a body mass index above 25. Negative correlations were found between plasma glucose and CMRgl in the left prefrontal and bilateral occipital regions. These associations may have functional implications since glucose levels in turn were negatively associated with neuropsychological test scores. Conclusion: Plasma apoE3 but not apoE4 may be involved in insulin-independent processes governing plasma glucose levels. Higher plasma glucose, which negatively affects brain glucose metabolism, was associated with lower plasma apoE levels in APOE ɛ3/ɛ4 subjects. High plasma glucose and low apoE levels may be a hazardous combination leading to an increased risk of AD.
Several faces of refractory coeliac disease type 2
Murray, Joseph A. , Murray, J A

Mayo Clinic

Gut | March 30, 2021 | Volume: 71 | Issue: 3 | Pages: 449-450

10.1136/gutjnl-2021-324251 | PMID 33785554 Get It

Abdominal pain and leg lesions: is there a connection?
Kapoor, Ankita , Hayat, Muhammad Hashim , Yousaf, Amman , Tariq, Raseen , Tariq, Raseen

Mayo Clinic

BMJ Case Reports | March 30, 2021 | Volume: 14 | Issue: 3 | Pages: e242422

10.1136/bcr-2021-242422 | PMID 33785606 Get It

In Vivo Efficacy of Tesevatinib in EGFR -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
Kizilbash, Sani H. , Gupta, Shiv K. , Parrish, Karen E. , Laramy, Janice K., Kim, Minjee , Gampa, Gautham, Carlson, Brett L. , Mladek, Ann C. , Decker, Paul A. , Elmquist, William F. , Bakken, Katrina K. , Schroeder, Mark A. , Kizilbash, Sani H , Mladek, Ann C , Gupta, Shiv K , Decker, Paul A. , Sarkaria, Jann N.

Mayo Clinic

Molecular Cancer Therapeutics | March 30, 2021 | Volume: 20 | Issue: 6 | Pages: 1009-1018

10.1158/1535-7163.mct-20-0640 | PMID 33785646 Get It

Abstract Tesevatinib is a potent oral brain penetrant EGFR inhibitor currently being evaluated for glioblastoma therapy. Tesevatinib distribution was assessed in wild-type (WT) and Mdr1a/b(-/-)Bcrp(-/-) triple knockout (TKO) FVB mice after dosing orally or via osmotic minipump; drug–tissue binding was assessed by rapid equilibrium dialysis. Two hours after tesevatinib dosing, brain concentrations in WT and TKO mice were 0.72 and 10.03 μg/g, respectively. Brain-to-plasma ratios (Kp) were 0.53 and 5.73, respectively. With intraperitoneal infusion, brain concentrations were 1.46 and 30.6 μg/g (Kp 1.16 and 25.10), respectively. The brain-to-plasma unbound drug concentration ratios were substantially lower (WT mice, 0.03–0.08; TKO mice, 0.40–1.75). Unbound drug concentrations in brains of WT mice were 0.78 to 1.59 ng/g. In vitro cytotoxicity and EGFR pathway signaling were evaluated using EGFR-amplified patient-derived glioblastoma xenograft models (GBM12, GBM6). In vivo pharmacodynamics and efficacy were assessed using athymic nude mice bearing either intracranial or flank tumors treated by oral gavage. Tesevatinib potently reduced cell viability [IC50 GBM12 = 11 nmol/L (5.5 ng/mL), GBM6 = 102 nmol/L] and suppressed EGFR signaling in vitro. However, tesevatinib efficacy compared with vehicle in intracranial (GBM12, median survival: 23 vs. 18 days, P = 0.003) and flank models (GBM12, median time to outcome: 41 vs. 33 days, P = 0.007; GBM6, 44 vs. 33 days, P = 0.007) was modest and associated with partial inhibition of EGFR signaling. Overall, tesevatinib efficacy in EGFR-amplified PDX GBM models is robust in vitro but relatively modest in vivo, despite a high brain-to-plasma ratio. This discrepancy may be explained by drug-tissue binding and compensatory signaling.
Severe urticarial rash as the initial symptom of COVID-19 infection
Pagali, Sandeep R. , Parikh, Riddhi S. , Pagali, Sandeep

Mayo Clinic

BMJ Case Reports | March 30, 2021 | Volume: 14 | Issue: 3 | Pages: e241793

10.1136/bcr-2021-241793 | PMID 33766974 Get It

A 54-year-old woman presented with pruritic rash and hives of 3 days’ duration followed by shortness of breath for 1 day. SARS-CoV-2 PCR test for COVID-19 was positive. Cutaneous manifestations of COVID-19 include acral lesions, urticarial rash, erythematous maculopapular rash, vascular rashes and vesicular rash. The cutaneous manifestations are mostly described as self-limiting. Urticarial rashes are not reported as the initial presentation symptom of COVID-19 infection but mostly noted to occur at the same time or after the onset of non-cutaneous symptoms. Management of cutaneous manifestations of COVID-19 affecting quality of life has not been well studied. Antihistamine therapy is the primary recommended therapy. Role of antiviral therapy for severe cases of rash needs to be further assessed.